1. Home
  2. CRBP vs EFTY Comparison

CRBP vs EFTY Comparison

Compare CRBP & EFTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBP
  • EFTY
  • Stock Information
  • Founded
  • CRBP 2009
  • EFTY 2013
  • Country
  • CRBP United States
  • EFTY Hong Kong
  • Employees
  • CRBP N/A
  • EFTY N/A
  • Industry
  • CRBP Biotechnology: Pharmaceutical Preparations
  • EFTY
  • Sector
  • CRBP Health Care
  • EFTY
  • Exchange
  • CRBP Nasdaq
  • EFTY Nasdaq
  • Market Cap
  • CRBP 114.8M
  • EFTY 113.6M
  • IPO Year
  • CRBP N/A
  • EFTY 2025
  • Fundamental
  • Price
  • CRBP $9.50
  • EFTY $8.07
  • Analyst Decision
  • CRBP Strong Buy
  • EFTY
  • Analyst Count
  • CRBP 10
  • EFTY 0
  • Target Price
  • CRBP $53.22
  • EFTY N/A
  • AVG Volume (30 Days)
  • CRBP 91.8K
  • EFTY 369.5K
  • Earning Date
  • CRBP 11-06-2025
  • EFTY 01-01-0001
  • Dividend Yield
  • CRBP N/A
  • EFTY N/A
  • EPS Growth
  • CRBP N/A
  • EFTY N/A
  • EPS
  • CRBP N/A
  • EFTY 0.05
  • Revenue
  • CRBP N/A
  • EFTY $2,525,909.00
  • Revenue This Year
  • CRBP N/A
  • EFTY N/A
  • Revenue Next Year
  • CRBP $220.04
  • EFTY N/A
  • P/E Ratio
  • CRBP N/A
  • EFTY $175.13
  • Revenue Growth
  • CRBP N/A
  • EFTY 3855.20
  • 52 Week Low
  • CRBP $4.64
  • EFTY $3.88
  • 52 Week High
  • CRBP $56.93
  • EFTY $8.68
  • Technical
  • Relative Strength Index (RSI)
  • CRBP 49.85
  • EFTY N/A
  • Support Level
  • CRBP $9.42
  • EFTY N/A
  • Resistance Level
  • CRBP $9.73
  • EFTY N/A
  • Average True Range (ATR)
  • CRBP 0.51
  • EFTY 0.00
  • MACD
  • CRBP -0.08
  • EFTY 0.00
  • Stochastic Oscillator
  • CRBP 15.33
  • EFTY 0.00

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About EFTY Etoiles Capital Group Co. Ltd. Class A Ordinary Shares

Etoiles Capital Group Co Ltd specializes in providing integrated investor relations services within the financial industry.

Share on Social Networks: